News + Resources

Keep up with the latest

Featured

This Scientist Is Building Custom Gene-Editing Tools

This Scientist Is Building Custom Gene-Editing Tools

Scribe Therapeutics Reports Preclinical Data Validating its CRISPR Genome Editing and Epigenome Modifying Technologies for Addressing Cardiometabolic Disease at American Heart Association (AHA) Scientific Sessions 2024

November 25, 2024

Scribe Therapeutics Reports Preclinical Data Validating its CRISPR Genome Editing and Epigenome Modifying Technologies for Addressing Cardiometabolic Disease at American Heart Association (AHA) Scientific Sessions 2024

November 25, 2024

CRISPR 2.0, the Next Generation

June 21, 2024

Aspen Ideas: Health

CRISPR 2.0, the Next Generation

June 21, 2024

The Age of CRISPR: Engineering the Future of Genetic Medicine

February 23, 2024

TEDxBerkeley

The Age of CRISPR: Engineering the Future of Genetic Medicine

February 23, 2024

Scribe Therapeutics Picks Cholesterol-Lowering As First In Vivo Gene Target

February 7, 2024

Scrip

Scribe Therapeutics Picks Cholesterol-Lowering As First In Vivo Gene Target

February 7, 2024

All Stories

All
News
Press Releases
News

Industry appetite for natural killer cells intensifies

February 15, 2023

Nature Biotechnology

Read Now
News

Economic Forecast 2023

January 6, 2023

San Francisco Business Times

Read Now
News

Building a biotech in a downturn: 3 lessons from VCs and startup CEOs

November 3, 2022

Biopharma Dive

Read Now
News

Deals In Depth: September 2022

October 18, 2022

In Vivo

Read Now
News

Scribe and Sanofi partner to develop cell therapies for cancer

September 28, 2022

Pharmaceutical Technology

Read Now
News

Follow the Money

September 28, 2022

Bio-IT World

Read Now
Press release

Scribe Therapeutics Expands In Vivo Collaboration with Sanofi to Second Target

January 3, 2024

Read Now
Press release

Scribe Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

January 2, 2024

Read Now
Press release

Scribe Therapeutics Appoints Dr. Aarif Khakoo as Chief Scientific Officer and Head of Research and Development, and Dr. Maria Mirotsou as Vice President of Discovery Biology

December 20, 2023

Read Now
Press release

Scribe Therapeutics Expands Collaboration with Sanofi to Advance In Vivo Genetic Medicines for Sickle Cell and Other Genomic Diseases

July 17, 2023

Read Now
Press release

Scribe Therapeutics to Participate in Upcoming Investor Conferences in May and June

May 22, 2023

Read Now
Press release

Scribe Therapeutics Presents Data on its X-Editing Technologies at 2023 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

May 19, 2023

Read Now

Publications